Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease by G. Melli et al.
RESEARCH ARTICLE
Cervical skin denervation associates with alpha-synuclein
aggregates in Parkinson disease
Giorgia Melli1,2 , Elena Vacchi1, Vanessa Biemmi1, Salvatore Galati1,2, Claudio Staedler2,
Roberto Ambrosini3 & Alain Kaelin-Lang1,2,4
1Laboratory for Biomedical Neurosciences, Neurocentre of Southern Switzerland, Via ai S€oi 24. CH-6807, Torricella-Taverne, Switzerland
2Neurology Department, Neurocentre of Southern Switzerland, Via Tesserete 46, CH-6900, Lugano, Switzerland
3Department of Environmental Science and Policy, University of Milan, Via Celoria 26, I-20133, Milan, Italy
4Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 4,3010, Bern, Switzerland
Correspondence
Giorgia Melli, Laboratory for Biomedical
Neurosciences, Neurocentre of Southern
Switzerland, Via ai S€oi 24. CH-6807,
Torricella-Taverne, Switzerland.
Tel: +41 (0)91 8116535; Fax: +41 (0)91
8116915; E-mail: giorgia.melli@eoc.ch
Funding Information
We thank Parkinson Schweiz and ABREOC
(the Scientific Research Advisory Board of the
Ente Ospedaliero Cantonale) for their
financial support of this study.
Received: 24 July 2018; Revised: 17
September 2018; Accepted: 19 September
2018
Annals of Clinical and Translational
Neurology 2018; 5(11): 1394–1407
doi: 10.1002/acn3.669
Abstract
Objective: Autonomic nervous system is involved at the onset of Parkinson
disease (PD), and alpha-synuclein (a-Syn) and its phosphorylated form (p-
aSyn) have been detected in dermal autonomic nerve fibers of PD. We
assessed disease specific conformation variant of a-Syn immunoreactivity in
cutaneous nerves and characterized skin denervation patterns in PD and
atypical parkinsonism (AP). Methods: We enrolled 49 subjects, 19 with PD,
17 age-matched healthy controls, and 13 with AP. The manifestations of dis-
ease were rated on clinical scales. Skin biopsies from ankle, thigh, and neck
were analyzed by immunofluorescence for p-aSyn, 5G4 as a conformation
specific antibody to pathogenic a-Syn and PGP9.5 as axonal marker.
Intraepidermal nerve fiber density was measured in all anatomical sites as
marker of neurodegeneration. Thirteen of the 19 PD underwent a 1 year fol-
low-up visit plus skin biopsies. Results: PD subjects displayed more severe
cervical skin denervation (P < 0.03), which correlated to disease duration
and worsened between initial and follow-up examination (P < 0.001). p-aSyn
and 5G4 were equally sensitive and specific for the diagnosis of PD (area
under the ROC was 0.839 for p-aSyn and 0.886 for 5G4). PD and AP with
possible alpha-synucleinopathies share the features of marked cervical dener-
vation and the presence of 5G4. In contrast AP with possible tauopathies
were normal. Interpretation: Conformational specific forms of a-Syn are
detectable in skin biopsy by immunofluorescence in PD, with a promising
diagnostic efficiency similar to p-aSyn. Cervical cutaneous denervation corre-
lates with disease duration and increases over time standing out as a poten-
tial biomarker of PD progression.
Introduction
The diagnosis of PD still relies exclusively on clinical signs
of motor involvement that appear after significant neu-
rodegeneration has already occurred. Hence, there is a
strong need for reliable biomarkers, so that treatment can
be started early for maximum impact and clinical trials of
disease-modifying drugs can be conducted. Many studies
have revealed Lewy bodies, the hallmark of PD pathology,
in peripheral tissues, and Braak intriguingly hypothesized
that alpha-synuclein (a-Syn) pathology may begin in the
peripheral nervous system well before it appears in the
brain.1 In fact, non-motor autonomic symptoms, includ-
ing gastrointestinal and cutaneous manifestations, are
common in early PD.2 Nearly two-thirds of patients with
PD complain of thermoregulatory, cutaneous vasomotor,
and sweating disturbances.3
a-Syn deposits have been demonstrated by immunohis-
tochemistry in cutaneous autonomic fibers in PD
patients, and the amount of a-Syn correlates with mea-
sures of autonomic dysfunction.4 Phosphorylated a-Syn
(p-aSyn) deposition in PD patients has been found in the
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autonomic nerves surrounding sweat glands and pilomo-
tor muscles.5–7 Positive skin biopsies for p-aSyn have
been found in 73–75% of patients with PD or multiple
system atrophy (MSA)8 and in patients with Lewy body
dementia.9 Two promising studies have shown that der-
mal p-aSyn can be detected in a subgroup of patients
with REM-sleep behavioral disturbances (RBD), poten-
tially representing prodromal PD.10,11 Another important
point emerging from these studies is that most PD
patients displayed cutaneous somatic and autonomic den-
ervation.4,6,12–16 However, the potential relationship
between pathological a-Syn deposits and the loss of small
nerve fibers is still unclear.
Thus even if skin biopsy is capable to distinguish PD
from healthy subjects, it lacks adequate sensitivity and
specificity and further studies are therefore needed to
achieve standardization of anatomical site and of
immunohistochemical process including the choice of the
antigen.17
Soluble oligomeric forms of misfolded proteins are the
early pathogenic species not only in PD but also in Alz-
heimer disease and other proteinopathies. In particular
misfolded a-Syn protein forms small oligomers that are
neurotoxic both in vivo an in vitro18,19. a-Syn oligomers
have been isolated from postmortem brains20,21 and,
more importantly in the plasma22 and cerebrospinal fluid
of living PD patients.23,24
Since p-aSyn is present in cutaneous nerves of PD, we
hypothesize that other disease specific forms of a-Syn
may be present there as well. In particular we exploit 5G4
antibody for the first time in skin biopsies: this is a con-
formation-specific monoclonal antibody with high reac-
tivity for disease specific forms of a-Syn including
oligomers in brain and low reactivity for monomeric a-
Syn.25,26 We investigate both the aggregates and phospho-
rylated a-Syn and innervation rate in skin biopsies in
three anatomical sites in PD, atypical parkinsonism (AP),
and healthy controls, plus a follow-up analysis at
12 months in PD. Our main aims are: (1) to test whether
a-Syn aggregates detection by 5G4 in skin biopsies can
serve as a biomarker of PD and/or AP and compare it to
p-aSyn detection, (2) to determine the diagnostic accu-
racy of skin biopsies at different anatomical sites, (3) to
measure skin innervation at baseline and its variation
with time at different anatomical sites as a biomarker of
disease progression.
Methods
Subjects
The Cantonal Ethics Committee approved the study pro-
tocol and all enrolled subjects gave written informed
consent to the study. Twenty-two consecutive patients
with idiopathic PD and 13 with AP followed by the
movement disorders outpatient clinic at NSI Lugano
were enrolled from July 2015 to December 2017. Inclu-
sion criteria for PD were: a definite clinical diagnosis
according to the UK Brain Bank diagnostic criteria, dis-
ease duration at least 3 years, no family history, and no
major cognitive impairment or major dysautonomic
symptoms in the history. In seven cases, the diagnosis
was supported by 123I-FP-CIT (DaTSCAN; GE Health-
care, Buckinghamshire, UK) showing typical dopaminer-
gic nigrostriatal denervation. Seventeen age-matched
healthy controls (HC) for the PD patients were recruited
among hospital staff and patients’ partners. The AP
group comprised patients in two subgroups: seven with
AP with possible alphasynucleinopathy pathology
(AP-SYN), including five with probable multiple system
atrophy and two with probable Lewy body dementia
according to published diagnostic criteria,27,28 and six
with AP with possible tauopathy pathology (AP-TAU),
including four with probable progressive supranuclear
palsy and two with possible corticobasal degenera-
tion.29,30 During the screening visit, all subjects under-
went a blood test for known causes of neuropathy
(glycated hemoglobin, creatinine, vitamin B12, TSH,
serum immunofixation, HIV, HCV, syphilis, and borre-
liosis), and three subjects (all PD group) who tested
positive were excluded. Scores on the following clinical
diagnostic instruments were determined: the Hoehn and
Yahr scale (H&Y) and MDS-UPDRS for the gravity of
disease (assessed by movement disorders experts), the
Mini-Mental State Examination (MMSE), the Montreal
Cognitive Assessment (MOCA), the Beck Depression
Inventory-II (BDI), and the REM Sleep Behavior Disor-
der Screening Questionnaire. The levodopa equivalent
daily dose (LEDD) was calculated for the PD patients.31
Thirteen of the 19 subjects with PD were reevaluated
in a follow-up visit at 12 months (T12) and underwent
a second round of skin biopsies and clinical assessment
scales as above. Of the remaining six patients, four
were lost to follow-up (because of disease progression
in one case and personal reasons in three cases), and
two were enrolled less than 12 months before the
analysis.
Skin biopsy
Each subject underwent six (3 mm-diameter) skin biop-
sies at three anatomical sites (two biopsies from the skin
of the neck at C8 dermatomal level), two from the thigh
10 cm below the trochanter, and two from the leg 10 cm
above lateral malleolus) on the side which was clinically
more affected, according to our standard technique.32
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For each anatomical site, one biopsy was fixed in
PLP2% fixative for immunofluorescence studies and one
biopsy was frozen and subsequently a RIPA extract was
prepared for biochemistry analysis.
Skin innervation
Skin innervation was assessed with a standard indirect
immunofluorescence technique on 50 lm thin tissue sec-
tions stained by free floating with an antibody specific for
the neuronal marker PGP9.5 (rabbit polyclonal, Abcam,
Cambridge UK, 1:1000). Cell nuclei were counterstained
for DAPI. PGP9.5 positive structures were counted to
determine the linear intraepidermal nerve fiber density
(IENFD) according to published standard protocols and
expressed as number of fibers/mm33,34 (Fig. 4A).
The same rater blind to the disease group, assessed all
skin biopsies at baseline and follow-ups.
Phosphorylated alpha synuclein and 5G4
immunofluorescence
Eight nonconsecutive 50 lm skin sections per site were
incubated overnight with a panel of primary antibodies:
PGP9.5, anti-p-aSyn, and 5G4 (Data S1).
Western blot analysis
The total amount of protein in the RIPA extracts obtained
from each skin biopsy was determined with the QuantiPro
BCA assay kit; 30 lg of protein was then subjected to SDS
polyacrylamide electrophoresis, transferred to PVDF mem-
branes, and probed with antibody against PGP9.5 and b-
actin (mouse monoclonal, Sigma Aldrige, Saint Louis, MO,
1:10.000). PGP9.5 quantification in skin extracts was deter-
mined by fluorescence intensity with an Odyssey CLx sys-
tem (Li-cor Biosciences, Lincoln, Nebraska) and
normalized to b-actin signal for each subject at each site.
Statistical analysis
Comparisons across groups of patients were performed
with Welch t-tests. Analyses of denervation at different
sites were run with mixed models including the subject as
a random factor (Data S1).
Results
Patients
The demographic data and clinical assessments in each
group are summarized in Table 1. AP-TAU subjects result
statistically older than HC group (P = 0.031), more
depressed (P = 0.008), and with a greater cognitive
impairment (P = 0.002) compared to PD and AP-SYN.
AP groups share a more severe disease gravity measured
by H&Y compared to PD subjects (AP-SYN P < 0.001,
AP-TAU P < 0.001).
Phosphorylated alpha synuclein and 5G4
positive deposits are significantly more
expressed in PD
In PD subjects, pathological a-Syn was significantly more
highly expressed, being detected mainly in dermal nerve
fascicles innervating autonomic structures, namely sweat
glands, muscle arrector pilorum (MAP), and arterioles,
while no staining of epidermal nerve fibers was found in
any group (Figs. 1, 2). P-aSyn was found to a signifi-
cantly greater extent in the PD group than in all others
(z ≥ 2.64, P(FDR) ≤ 0.03); the extent of its presence did
not vary significantly among sites (likelihood-ratio test:
v22 = 1.58, P = 0.45) (Fig. 1I–J) or between the two sexes
(v21 = 0.34, P = 0.56). In PD group, 5G4-positive struc-
tures were expressed to a significantly greater extent than
in the healthy subjects or in the AP-TAU patients
(z ≥ 2.87, P(FDR) = ≤0.01), and in AP-SYN patients more
than in the AP-TAU ones (z ≥ 2.29, P(FDR) = 0.04).
Moreover, AP-SYN patients expressed 5G4 positive struc-
tures at similar levels to PD patients (z ≥ 1.98,
P(FDR) = 0.07) but to a lesser extent in cervical area
(Fig. 2I–J). Finally, 5G4 positive structures were more
highly expressed in male than in female patients
(v21 = 0.4.75, P = 0.03), but at similar levels at all three
sites (likelihood-ratio test: v22 = 0.38, P = 0.83).
A major colocalization area was measured in PD for
both 5G4 and p-aSyn with a proximal to distal gradient
(Figs. 1P and 2P). However this analysis is limited by the
fact that sweat glands were not available for all subjects
and that a sweat gland denervation would increase the
ratio.
No significant difference in p-aSyn deposits was found
at T12 (|z| ≤ 0.95, P ≥ 0.35), while temporal changes in
the expression of 5G4 deposits between T0 and T12 dif-
fered among sites (likelihood-ratio test for the effect of
the site x time interaction: v22 = 10.18, P = 0.006). How-
ever, post hoc tests did not demonstrate any significant
pairwise difference between sites (|z| ≤ 0.04, P ≥ 0.97),
perhaps because of the small number of skin biopsies
available for this analysis.
5G4 versus p-aSyn detection: sensitivity and
specificity
When considering at least two positive sites for p-aSyn,
we found that nine out of 16 PD (56%) were positive, 0/
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12 in controls, 0/7 in AP-SYN and 0/6 in AP-TAU; for
5G4 in PD group 13/16 were positive (81.3%), 2/14
(14%) in controls, 4/7 in AP-SYN (57.1 %), and 0/7 in
AP-TAU.
Thus for PD group p-aSyn had 56% of sensitivity
and 100% of specificity respect controls and AP-SYN
and AP-TAU; 5G4 had 81% of sensitivity and 86%
specificity respect healthy controls, 43% specificity
respect AP-SYN, 100% specificity respect AP-TAU. In
AP-SYN 5G4 had a sensitivity of 57% and specificity of
19% respect PD and 86% respect controls, 100%
respect AP-TAU
We calculated the sensitivity and specificity of p-aSyn
and 5G4 in diagnosing PD at each anatomical site, as sum-
marized in Figure 3A. The worst performance was with p-
aSyn in the thigh and the best performance was with 5G4
in the neck (P = 0.054). The diagnostic yield of a combina-
tion of tests run with p-aSyn, 5G4, and both antibodies at
Table 1. Demographic data and clinical scores of patients with PD, AP and healthy controls.
PD T0 PD T12 AP-SYN AP-TAU HC
Number and gender 19
13 Male,
6 Female
13
10 Male,
3 Female
7
3 Male,
4 Female
6
2 Male,
4 Female
17
9 Male,
8 Female
Median age (years)
(quartiles)
66
(56.5/73)
67
(61/80)
72
(66/73.5)
76.5 * (71.5/77.8) 57
(54/72)
Median disease duration (years) (quartiles) 4.5
(3/7.8)
6
(4/9)
5.5
(2.8/7.5)
4
(3.3/4.8)
–
Median H&Y Scale
(quartiles)
2
(1/3)
2
(2/2)
5 ***
(3.5/5)
4.5 ***
(4/5)
–
% Patients treated
with L-DOPA
73.7% 69% – – –
LEDD (mg)
(quartiles)
587.5 (337.5/762.5) 495
(300/700)
– – –
Median Beck Depression Scale (quartiles) 6
(2.5/8.5)
9
(4/12)
8
(3.8/13)
14 **
(11.8/15.5)
–
Median MDS-UPDRS (quartiles) 22.50 (15.3/30.5) 19
(13.5/26)
– – –
Median RBD
(quartiles)
3
(1.5/4)
3
(2/5)
3
(1.3/4.8)
2.5
(0.3/4.8)
–
Median MMSE
(quartiles)
29
(28.5/30)
30
(28/30)
28
(26.3/29)
24 **
(22/28)
–
Median MOCA
(quartiles)
27
(23.5/28.5)
27
(20/28)
24.5
(21.5/26)
22
(16/23.5)
–
PD, control, and AP-SYN groups did not differ in age, (Tukey post hoc test : |t45| ≤ 2.02, P ≥ 0.19), while the APTAU subjects were significantly
older than the healthy controls (Tukey post hoc test: t45 = 2.85, P = 0.03). AP-TAU and AP-SYN had a more severe disease as measured by H&Y
compared to PD subjects (P < 0.001). The sex ratio did not differ across patient groups (binomial GLM: v23 = 3.01, P = 0.39). AP-TAU subjects
had significantly lower MMSE scores (Tukey post hoc test: t27 = 3.74, P = 0.002) and significantly higher scores on the Beck Depression Inven-
tory (Tukey post hoc test: t28 = 3.23, P = 0.01) compared to PD group, while AP-SYN subjects had intermediate values of both scores, not differ-
ing significantly from either the AP-TAU group or the PD group (Tukey post hoc test: |t27| ≤ 2.05, P ≥ 0.12). There was no significant difference in
disease duration in the PD, AP-SYN, and AP-TAU groups (Poisson GLM: v22 = 1.22, P = 0.54). *P < 0.05; **P < 0.01; ***P < 0.01.
PD, Parkinson Disease; AP, atypical parkinsonism; AP-SYN, atypical parkinsonism with synucleinophaties; AP-TAU, Atypical Parkinsonism with tauo-
pathies; HC, healthy control; H&Y scale: Hoen and Yahr scale; LEDD, levodopa equivalent daily dose; MDS-UPDRS, Movement Disorder Society -
Unified Parkinson’s Disease Rating Scale; RBD, REM sleep behavior disorder screening questionnaire; MMSE, minimental state examination; MOCA,
montreal cognitive assessment.
Figure 1. Phosphorylated alpha synuclein deposits are more expressed in PD. Confocal images of immunofluorescence with PGP9.5 (green) and
p-aSyn (red) of dermal nerves around sweat glands in PD T0 (A–B), in AP-SYN (D–E), AP-TAU (G–H), and healthy subject (J–L). In yellow
colocalization of p-aSyn and PGP 9.5 (C,F,I,M) along axons. Scale bar 50 lm. White arrows indicate positive structures, asterisks indicate
unspecific staining in non-neuronal structures. The percentage of p-aSyn is higher in PD T0 patients compared to other groups (P = 0.028) (N),
but is not different among localizations (O). A major colocalization area p-aSyn/PGP9.5 was measured in PD with a proximal to distal gradient (P).
PD, Parkinson disease.
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all anatomical sites was assessed by ROC curves (Fig. 3B).
The area under the ROC was 0.839 for p-aSyn (SE = 0.066;
95% CI = 0.699–0.951) and 0.886 for 5G4 (SE = 0.054;
95% CI = 0.759–0.970). The difference between areas was
0.047 (SE = 0.058; 95% CI = 0.067 to 0.164; P = 0.42).
The AUC of a test employing both antibodies was 0.863
(SE = 0.069; 95% CI = 0.713–0.983), and did not differ
significantly from the AUC of the tests with p-aSyn or 5G4
alone (P ≥ 0.34).
Since the best results were achieved with 5G4 in the
neck, we also assessed the diagnostic efficiency of testing
both antibodies in the neck only. The AUC was 0.899 for
5G4 (SE = 0.056, 95% CI = 0.774–1.000), 0.753 for p-
aSyn (SE = 0.081, 95% CI = 0.589–0.900) and 0.871 for
p-aSyn + 5G4 (SE = 0.055, 95% CI = 0.750–0.965).
Cervical skin denervation is a biomarker of
PD progression
PD group shows reduced epidermal nerve fibers
density at all anatomical sites, and gender affects
denervation
In Figure 4 immunofluorescence images of innervation of
epidermis and dermal autonomic structures are shown
for PD and healthy controls. The results of the mixed-
model analysis of IENFD are summarized in Table 2. In
all groups, the IENFD depends significantly on the site of
nerve biopsy, with a greater epidermal innervation density
in the neck (Tukey post hoc tests: t72.8 ≥ 6.11, P < 0.001)
and a proximal-to-distal gradient effect in accordance
with previous report (Fig. 5C). The IENFD was lower in
the PD group than in the HC and AP-TAU groups
(t40.8 < 2.33, P < 0.03), but not the AP-SYN group
(t38.4 = 0.44, P = 0.66), independently of anatomical site,
as indicated by the nonsignificant site x group interaction.
The IENFD of AP-TAU patients also tended to be higher
than that of AP-SYN ones, although this difference was
not statistically significant (t41.8 = 1.71, P = 0.09)
(Fig. 5A). Difference in IENFD among groups also varied
according to sex. Indeed, the IENFD was significantly
lower in women in the PD group than in healthy women
(t34.9 = 3.4, P = 0.002) and in AP-TAU women
(t36.2 = 4.04, P < 0.001), but not in women in the AP-
SYN group (t36.6 = 1.60, P = 0.12). Women with PD also
had lower IENFD values than men with PD (t35.6 = 2.64,
P = 0.01). In addition, the IENFD values of women in
the AP-SYN group were lower than those of women in
the AP-TAU group (t37.9 = 2.24, P = 0.03). In contrast,
there was no significant difference across groups for male
subjects (t40.1 = 0.93, P ≥ 0.36) (Fig. 5B). Age did not
significantly affect IENFD values.
Cervical cutaneous denervation is correlated with
disease duration and increases over time
Differences between PD patients and healthy controls in
the PGP9.5 measurements obtained by Western blot were
significantly larger at cervical site, as indicated by the
Figure 2. 5G4 deposits are more expressed in PD and AP-SYN patients. Confocal images of immunofluorescence with PGP9.5 (green) and 5G4
(red) of dermal nerves around sweat glands in PD T0 (A–B), AP-SYN (D–E), AP-TAU (G–H), and healthy subject (J–L). In yellow colocalization of
5G4 and PGP 9.5 (C,F,I,M) along axons. Scale bar 50 lm. White arrows indicate positive structures, asterisks indicate unspecific staining in non-
neuronal structures. The percentage of 5G4 is higher in PD T0 compared to HC and AP-TAU (PFDR < 0.012), but not compared to AP-SYN, and in
AP-SYN more than in AP-TAU (PFDR = 0.04) (N); no significant differences among localizations but a tendency of higher 5G4 at cervical site in PD
(O). A major colocalization area 5G4/PGP9.5 was measured in PD with a proximal to distal gradient (P).
Figure 3. ROC analysis for p-aSyn and 5G4 in PD. Sensitivity and specificity tests with each antibody in each anatomical site. N° PD T0 and N°
HC are the number of subjects for which each test is available (A). Comparison of the diagnostic yield of test performed with p-aSyn (blue), 5G4
(red), both markers (green) and 5G4 in cervical area only (yellow) (B). Statistical power of the ROC curves was: p-aSyn (0.946), 5G4 (0.987), both
markers (0.987) and 5G4 in cervical area only (0.998).
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significance of the site x group interaction (df = 7,
F = 7.09, P = 0.02, Fig. 5D–E). Cervical skin denervation
was correlated with disease duration (Spearman’s correla-
tion: r = 0.59, n = 13, P = 0.03, Fig. 5F).
On follow-up at 12 months (T12), skin biopsies showed
that, in the PD group, the IENFD was significantly lower
than at baseline on the neck (difference = 12.0  2.6
SE, t40.6 = 4.63, P < 0.001 at Tukey post hoc tests) and
the thigh (7.7  2.4 SE, t39.6 = 3.24, P = 0.002), but not
the leg (0.1  2.2 SE, t39.6 = 0.03, P = 0.98) (Fig. 5C).
Cervical cutaneous denervation is more
pronounced in patients with more severe PD
We split the PD group at T0 into two subgroups accord-
ing to disease severity (H&Y score). Six patients had more
Figure 4. Skin innervation: intraepidermal nerve fiber density (IENFD). Immunofluorescence staining with anti-PGP9.5 (green) and DAPI (blue) of
cervical skin in an healthy subject (A) and PD (C); in A the dotted white line shows the border between epidermis and dermis: IENFD is calculated
as the number of nerve fibers (arrows) crossing the border per mm. Dermal nerve fibers around sweat glands are shown in an healthy subject (B)
and PD (D). The pictures shows skin denervation in PD more evident at level of autonomic nerve fibers of sweat gland. Scale bar 50 lm.
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severe disease (H&Y ≥ 3), and 13 had milder disease
(H&Y < 3). As shown in Figure 6, the subjects in the first
group were significantly older and had a shorter disease
duration (age: t12.759 = 4.08, P = 0.001; disease duration:
t13.595 = 2.74, P = 0.02). No difference in LEDD was
found (t13.049 = 0.001, P = 0.999). Mixed models
accounting for biopsy site and sex showed that, on assess-
ment at T0, the group with more severe PD displayed
similar levels of positivity to p-aSyn or 5G4 and similar
IENFD values to patients with less severe disease
(|t16.01| ≤ 1.25, P ≥ 0.23). However, a comparison of the
denervation values of the same patients at T0 and T12 in
a mixed model accounting for patient sex and
disease severity showed a significant worsening of
denervation at the cervical site only (t41.1 = 5.06,
P < 0.001; |t41.1| ≤ 1.56, P ≥ 0.13 for the other areas)
(Fig. 6D). The group with more severe disease is signifi-
cantly older and age can affect innervation, but at T12 a
significant denervation was measured selectively at cervi-
cal site only and not at distal sites where we would attend
a major denervation due to ageing since distal axons are
more exposed to metabolic and oxidative stress. Finally
IENFD did not correlate at any anatomical site with
LEDD at T0 and T12.
Figure 5. Cervical skin denervation correlates to disease duration and significantly increases at 12 months follow-up. IENFD is lower in PD T0
patients compare to AP-TAU and HC subjects (P < 0.03), but not compared with AP-SYN (A). Total IENFD is significantly reduced in PD females
versus PD males (P = 0.012), in PD females versus HC females (P = 0.002) and versus AP-TAU (P < 0.001) (B). In PD after 12 months IENFD is
significantly lower at the thigh (P = 0.002) and at the cervical site (P = 0.001) (C). Western blot of skin lysates (an example) (D). Densitometry of
PGP9.5 and b-actin bands measured by LICOR software (n = 12 PD, n = 8 HC) PGP9.5 values normalized to b-actin, show a major denervation at
cervical site (P < 0.05) (E). PGP9.5 quantification negatively correlates to disease duration at cervical site in PD at T0 (F).
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Discussion
The main new aspects of this study are the investigation
of disease associated a-Syn forms other than p-aSyn in
peripheral skin nerves of patients with PD and AP, the
finding that cervical skin denervation is a biomarker of
PD progression, and the further finding that gender
affects skin denervation. Aggregated a-Syn was detected
with 5G4, an antibody whose specificity and sensitivity
for oligomeric a-Syn were shown in previous stud-
ies.25,26,35 This is a novel, highly sensitive biomarker for
PD to be used in skin biopsies. We found that 5G4 posi-
tive deposits are present in skin dermal nerves, especially
in the nerves surrounding sweat glands and other auto-
nomic structures of dermis (a spatial distribution resem-
bling that of p-aSyn), and that they are as sensitive and
specific as p-aSyn for the clinical diagnosis of PD. Both
p-aSyn and 5G4 had highly favorable ROC curves
(Fig. 3) with only a small difference between their AUCs
that cannot be interpreted as showing the superiority of
either antibody. In addition, 5G4 immunofluorescence
for cervical site only is just as effective in diagnosing PD
as immunofluorescence of samples from all three
anatomical sites. This is an important finding for simpli-
fying the procedure of sampling skin biopsies toward an
effective and less invasive biomarker search, and matches
the results of major denervation in the cervical area as
measured by Western blot of whole skin (epidermis and
dermis) lysates. While several independent groups have
found p-aSyn in dermal nerves (albeit with different
specificity and sensitivity) and others in the gastrointesti-
nal nervous plexus, submandibular glands,17,36 to our
knowledge this is the first evidence of aggregated a-Syn
evidence in cutaneous nerves. Counterintuitively we
found 5G4 positive staining also in heathy subjects, even
if to a significantly lesser extent. These results may have
several methodological explanations, alternatively, the
presence of 5G4 positive samples in the elderly healthy
population may be correct. In fact, incidental Lewy body
disease (ILBD) defined as cerebral Lewy body pathology,
is identified at autopsy in subjects without evidence of
antemortem neurological disorders. ILBD is found in 5
to 24% of people >60 years of age.37 Furthermore, aggre-
gated aSyn has been detected also in gastrointestinal
mucosa of healthy subjects36,38Conformation specific anti-
body to pathogenic a-Syn can bring important advan-
tages in the field of peripheral biopsies in
neurodegenerative disease. In fact care must be taken
when evaluating immunoreactivities with p-aSyn (at
Ser129) antibody, since it may cross-react with phospho-
rylated low-molecular weight neurofilament subunits, and
cellular stresses or insults can greatly increase the phos-
phorylation state of many proteins, including p-aSyn at
Ser129.39,40 Plus aSyn oligomers are thought to be an
early neurotoxic agent that plays a crucial role at the
beginning of the neurodegenerative cascade leading to PD
while the pathogenic role of p-aSyn is more controversial.
Marked accumulation of it (>90%) has been reported in
brain Lewy bodies, which implies an important role in
the regulation of a-Syn aggregation, yet it is still debated
whether phosphorylation at the residue S129 enhances or
suppresses a-Syn aggregation and toxicity.41 Indeed, p-
aSyn could be a late event in disease progression, pro-
moting the “disaggregation” of inclusion bodies and
enhancing their degradation.42 Hence, the high sensitivity
and non-inferiority of a-Syn aggregates detected by 5G4
antibody vs p-aSyn in cervical cutaneous nerves, if are
replicated in other studies, especially in early and premo-
tor PD, may represent an important step toward the
detection of an early biomarker of PD disease. In fact, in
this analysis we focused on patients with well established
clinical diagnoses and a long duration of disease in order
to avoid confounding data in cases of uncertain diagno-
sis, particularly in the early phases.
Table 2. IENFD analysis in PD, AP and HC subjects.
Variable Sum Sq Mean Sq NumDF DenDF F P
Site 2281.66 1140.83 2 74.568 37.040 <0.001
Group 300.81 100.27 3 38.540 3.256 0.032
Gender 26.35 26.35 1 40.352 0.855 0.361
Age 0.12 0.12 1 38.251 0.004 0.951
Site*Group 284.70 47.45 6 73.050 1.541 0.177
Site*Gender 38.61 19.31 2 74.550 0.627 0.537
Group*Gender 355.36 118.45 3 38.928 3.846 0.017
Site*Group*Gender 249.64 41.61 6 73.035 1.351 0.246
Results of mixed-model analysis of IENFD in relation to anatomical site, patient group, gender, and age and to the two and three way interactions
among anatomical site and patient group and gender. Patient identity was included as a random grouping factor. Age was included as a
covariate.
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Another important finding of this study is that patients
with PD display marked epidermal denervation as mea-
sured by IENFD. The more severe denervation in cervical
skin biopsies as revealed by Western blot in comparison
to IENFD may be explained by the fact that the entire tis-
sue samples with both epidermal and dermal nerve fibers
are measured by Western blot, while the IENFD measures
epidermal innervation only. Perhaps neurodegeneration is
more severe in the dermis, which is also the area where
the deposits of pathological misfolded a-Syn are mainly
found.7,43 Moreover, cervical skin denervation positively
correlates with disease duration and is a marker of disease
severity, as shown by the fact that more severely affected
patients had greater denervation at this site on follow-up
at 12 months. Thus, cervical skin denervation alone is an
interesting potential marker of neurodegeneration and
disease progression in PD independently of pathological
a-Syn deposits. As we excluded confounding factors such
as vitamin deficiency or levodopa therapy, it is unlikely
that this finding is due to other factors than the disease
itself. The finding of a trend toward greater accumulation
of pathologic a-Syn in the skin of the neck was statisti-
cally insignificant; however, it remains to be clarified
whether denervation is a direct local effect of a-Syn aggre-
gation or an indirect neurotoxic effect mediated by long-
distance cell-body signaling leading to the accumulation
of pathogenic a-Syn. It has been shown that a-Syn prefer-
entially aggregates in neurons with long, hyperbranching,
thin, and unmyelinated axons, such as the axons of the
nigrostriatal projection, the cardiac sympathetic system,
the vagal intestinal autonomic system,1,39,44 and skin.
Orimo et al44 showed that a-Syn aggregates in cardiac
sympathetic distal axons precedes the accumulation in
neuronal cell bodies and heralds centripetal axonal degen-
eration, since we measured intraepidermal somatic sen-
sory axons density while aggregated a-Syn were found
mainly in autonomic nerve structures, a quantification of
autonomic nerves is mandatory to verify this theory in
skin.
This study shows a robust denervation in PD patients
at all skin sites that is most pronounced on the neck, with
a proximal-to-distal gradient, the opposite of what is clas-
sically observed in dying-back, length-dependent periph-
eral neuropathy. This supports a possible centrifugal
spread of pathology from the central nervous system
toward the periphery, mainly along the autonomic and
sensory nerves. This hypothesis, however, contrasts with
other studies on the diffusion of misfolded a-Syn from
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Figure 6. Cervical skin denervation in PD differs according to disease
gravity. PD patients were divided in two groups based on H&Y
severity. The group with H&Y ≥ 3 is significant older (P = 0.005) (A),
with a lower disease duration (P = 0.036) (B), and no difference in
LEDD (C). After 12 months IENFD denervation is greater in more
disabled patients at cervical site (P = 0.019) (D).
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the gastrointestinal peripheral system through the vagus
nerve by retrograde axonal transport to the medulla
oblongata. A multihit hypothesis has been proposed sug-
gesting that a-Syn deposition is not monofocally initiated
but may be induced by multiple independent factors (e.g.
infective agents or viruses) outside the central nervous
system through the nasal cavity or the digestive tract.39
Several genetic PD are characterized by considerable
variation in neuropathology and no a-Syn aggregates in
CNS. Our study included only sporadic PD, but it is
known that LRRK2 mutations are found in 1–2% of spo-
radic PD.45 However from cellular and animal models it
appears that LRRK2 kinase activity leads to phosphoryla-
tion of a-Syn46 thus it is still possible that LRRK2 muta-
tion carriers do harbor a-Syn pathology.
These data show that gender influences epidermal
innervation and pathological a-Syn accumulation: epider-
mal denervation was more severe in women with PD and
AP-SYN, while the presence of 5G4 at baseline and the
extent of denervation on follow-up at 12 months were
greater in men. These results are hard to explain in the
light of current knowledge, but they highlight the need to
take account of sex in the design of clinical trials and
biomarkers search studies. They are consistent with evi-
dence of sex differences in the prevalence, clinical course,
and motor and cognitive manifestations of PD.47 In addi-
tion, it is known that gender influence epidermal nerve
fibers density in healthy subjects,34 and females are more
prone to develop idiopathic small fiber neuropathy.48 P-
aSyn presence did not vary significantly between the two
sexes (P = 0.56) while 5G4 positive structures were more
highly expressed in male than in female patients
(P = 0.03). We can speculate that being 5G4 deposits pre-
sent presumably at the beginning of disease they are less
detectable after neurodegeneration has occurred and since
women showed a major denervation, 5G4 deposits were
fewer, however our analysis is underpowered to answer
the question if the differential denervation among sexes is
due to different presence of P-aSyn/5G4
Finally, skin denervation and pathological a-Syn may
also be useful as biomarkers for atypical parkinsonism, as
suggested by previous studies.8,10 In particular, they can be
used to distinguish between AP-TAU and AP-SYN. In fact,
PD and AP-SYN share the common features of significant
skin denervation and 5G4 positivity with respect to healthy
controls and AP-TAU, in accordance with their common
pathologic background linked to the presence of alpha-
synuclein accumulation. In particular, p-aSyn is more
specific for PD, while 5G4 presence did not statistically dif-
fer in AP-SYN but displays a lower expression and a differ-
ent distribution among skin biopsy sites, being found
mainly on the neck in PD and on the thigh and leg in AP-
SYN. Our group of AP-SYN, albeit small, included a
majority of probable-MSA (5 out of 7). The presence of p-
aSyn in MSA has been debated and conflicting results have
been reported,6,8 due to different anatomical site of biopsy
and different protocols of IF analysis.49 Our study protocol
is in line with the paper by Doppler8 and results are con-
cordant, however larger studies and unified protocols are
strongly needed for definitive evidence. We also found that
5G4 in MSA in contrast to PD is found mainly at distal
sites: aSyn accumulates in neurons and neurites in PD
while in MSA it accumulates in oligodendrocytes as glial
cytoplasmic inclusions. Interestingly it has been recently
demonstrated that distinct aSyn strains are generated by
different intracellular milieus.50 We can speculate that the
pathological spreading across the nervous system is also
differently influenced by different aSyn strains.
In conclusion, these results highlight the importance of
investigating different pathological antigens including
protein aggregates with different types of antibody in
order to improve the diagnostic yield of skin biopsy in
PD and AP.
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Supplementary material 
Methods 
Phosphorylated alpha synuclein and aggregated alpha synuclein immunofluorescence 
Primary antibodies were PGP9.5, anti-p-αSyn mouse antibody targeting phosphorylated serine 129 of human α-Syn 
(Wako Chemicals, Neuss, Germany, 1:1000) and the 5G4 (Analytik Jena Life Science, Jena, Germany, 1:400). 
The 5G4 is a mouse monoclonal antibody targeting disease specific forms of α-Syn including oligomers antibody and it 
has been widely used to detect high-molecular-weight α-Syn oligomers in brain tissues that are nitrated and display the 
typical beta-sheet conformation, with less binding to α-Syn fibrils and none to physiological, monomeric α-Syn 26, 35. 
The weak detection of monomeric α-Syn by 5G4 is possibly because the epitope is not available in an unfolded 
conformation 25. In fact, the epitope recognized by 5G4 (amino  acids 46-53) starts after the interruption of the alpha-
helical structure of physiological α-Syn at amino acid 43-44 51 and terminates at amino acid 53(A), which may harbor 
an A53T mutation and could influence the aggregating ability of α-Syn 52.  
Secondary antibodies were AlexaFluor 488 goat anti-rabbit and AlexaFluor 594 goat anti-mouse (ThermoFisher 
Scientific, Waltham, USA, 1:400). 
Tissue sections were counter-stained for PGP9.5 and DAPI to detect the specific co-localization of p-αSyn and 5G4 
within nerves. Sections were viewed under an inverted fluorescence microscope (Nikon Eclipse Ti-E, Tokyo, Japan) 
and selected sections were also analyzed with a Nikon confocal microscope (40x or 20x magnification, successive 
frames of 2µm increments on a Z-stack plan) using NIS Elements 4.11.01 imaging software. The presence or absence of 
positive structures (5G4/PGP9.5 or p-αSyn/PGP9.5 or both) at each site across groups was assessed by an independent 
examiner who was blinded to the clinical diagnosis. Since most commercial antibodies cross react to monomeric 
physiological αSyn in epithelial cells, only structures which show double staining PGP9.5 and p-αSyn/5G4 were 
considered positive. Unspecific sweat glands acinus intraluminal fluorescent precipitates and sweat glands tubules 
autofluorescence was carefully excluded. A subject was classified as positive if at least one biopsy site showed nerve 
fibers immune-reactive to p-αSyn or 5G4. The number of positive biopsy sites per subject was recorded. Co-localization 
area of p-αSyn/PGP9.5 and 5G4/PGP9.5 was measured in at least 1 sweat gland for location for subject in each group 
(2-5 subjects for group for location). 
 
Statistical analysis. Comparisons across groups of patients were performed with Welch t-tests. Analyses of denervation 
at different sites were run with mixed models including the subject as a random factor. These models are similar to 
repeated-measure ANOVAs, but have the advantage that all subjects do not need to have the same number of repeated 
measures 53. Analyses were run in R 3.2.2 with the lmer procedure in the lme4 (1.1-14) library, the glmmadmb 
procedure in the glmmADMB (0.8.3.3) library and post-hoc tests (Tukey method) with the lsmeans and difflesmens 
procedures in the lmerTest (2.0-33) library. Similarly, models of positivity to p-αSyn and 5G4 were run by binomial 
generalized linear mixed models (GLMMs) fitted with the glmer procedure. Since procedure for post-hoc tests were not 
available for GLMMs, we performed comparisons between pairs of levels of the factors of interest with multiple 
GLMMs including only the levels under scrutiny, while correcting significance with the false discovery rate method 
according to the Benjamini-Hockberg procedure 54 in the multtest (2.30.0) library of R to account for multiple statistical 
tests. Analysis of PGP9.5 measurement obtained by Western blot was performed by a repeated measure ANOVA run in 
SPSS (v.20 IBM Corp, Armonk, NY). 
The diagnostic yields of tests performed with each antibody on each body area was estimated by the area under the 
receiver operating characteristic (ROC) curve. Standard error (SE) and 95% confidence interval (95% CI) of the area 
under the curve (AUC) was assessed by a stratified bootstrap with 2000 repetitions. Bootstrap was also used to compare 
the AUC of two ROC curves. Analyses were performed with the pROC (1.10.0) library of R. 
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